IBIO Stock – IBIO Stock: The Covid-19 Vaccine News Sending iBio Soaring Today
Ibio (NYSEAMERICAN:IBIO) stock is soaring higher on Friday after announcing a next-generation vaccine program to treat the novel coronavirus.
This new program has it developing IBIO-202 for the prevention of coronavirus. The candidate uses antigens derived from the spike protein fused with its own LicKM booster molecule.
The positive news from that program today is the completion of IND-enabling toxicology studies. These studies found that there were no adverse effects at low or high doses from the vaccine candidate.
To go along with this, iBio is also working on the IBIO-202 vaccine candidate. This is also designed to treat coronavirus. However, it targets nucleocapsid protein instead of the spike protein. The advantage of this is that it could allow for better protection against mutant strains of the virus.